Prostate Cancer - Results from #19240

Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer - Abstract February 14, 2015

High-intensity focused ultrasound for the treatment of prostate cancer: A prospective trial with long-term follow-up - Abstract February 14, 2015

Risk factors for PSA bounce following radiotherapy: Outcomes from a multi-modal therapy analysis - Abstract February 14, 2015

A randomised controlled trial of a couples-based sexuality intervention for men with localised prostate cancer and their female partners - Abstract February 14, 2015

Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: A meta-analysis - Abstract February 14, 2015

Five-year follow-up of active surveillance for prostate cancer: A Canadian community-based urological experience - Abstract February 14, 2015

American trends in expectant management utilization for prostate cancer from 2000 to 2009 - Abstract February 14, 2015

Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic - Abstract February 14, 2015

A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer - Abstract February 14, 2015

Advances in systemic therapies for metastatic castration-resistant prostate cancer - Abstract February 13, 2015

Survival outcomes of Chinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate-specific antigen nadir level - Abstract February 13, 2015

Immunotherapy in prostate cancer: Review of the current evidence - Abstract February 13, 2015

Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy - Abstract February 13, 2015

Clinical management and burden of prostate cancer: A Markov Monte Carlo mode - Abstract February 13, 2015

Safety of I.V. nonnitrogen bisphosphonates on the occurrence of osteonecrosis of the jaw: Long-term follow-up on prostate cancer patients - Abstract February 13, 2015

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml -1 and 10.1-20.0 ng ml -1: A multicenter study - Abstract February 13, 2015

Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: A systematic review and meta-analysis - Abstract February 13, 2015

Impact of the U.S. Preventive Services Task Force recommendations against PSA screening on prostate biopsy and cancer detection rates - Abstract February 13, 2015

Evolution of the number of incident cases of prostate cancer in France from 2001 to 2012 from 5 hospital centers - Abstract February 13, 2015

A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy - Abstract February 12, 2015

Page 963 of 1457